Integrated [68Ga]Ga-FAPI-7ND PET/CT and stromal profiling of immunocompetent syngeneic tumor models for FAP-targeted radionuclide therapy.
In 4 T1 tumors, [177Lu]Lu-FAPI-7ND showed antitumor activity accompanied by immune microenvironmental alterations, supporting integrated model selection for immunocompetent FAP-RNT studies.